Inactive Instrument

ADVANZ PHARMA Corp. Limited Stock

Equities

CXRXF

JE00BJVH6L55

Pharmaceuticals

Dynamic Chart
ADVANZ PHARMA Corp. Limited announced that it has received funding from Nordic Capital, Ontario Teachers' Pension Plan Board CI
ADVANZ PHARMA Corp. Limited signed an agreement to acquire Global rights of Androcur. CI
ADVANZ PHARMA Corp. Limited completed the acquisition of Global rights of Tostran from Kyowa Kirin Co., Ltd.. CI
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe CI
ADVANZ PHARMA Corp. Limited signed an agreement to acquire Global rights of Tostran from Kyowa Kirin Co., Ltd.. CI
Applied Therapeutics, Inc. Announces Partnership with Advanz Pharma for Commercialization of AT-007 in Europe CI
ADVANZ PHARMA Corp. Limited acquired Portfolio Of Generic Drugs Of Sanofi. CI
ADVANZ PHARMA Corp. Limited Names Andreas Stickler as New CFO CI
ADVANZ PHARMA Corp. Limited Limited Names Susanna El-Armale as Chief Corporate Development Officer CI
Steffen Wagner Assumes His Position as New Chief Executive Officer At ADVANZ PHARMA Corp. Limited CI
ADVANZ PHARMA Corp. Limited Announces Executive Changes CI
ADVANZ PHARMA Corp. Limited Announces Executive Changes CI
ADVANZ PHARMA Corp. Limited Announces Executive Changes CI
ADVANZ PHARMA : Nordic Capital Completes US$846 Million Acquisition of Advanz Pharma MT
Nordic Capital completed the acquisition of ADVANZ PHARMA Corp. Limited (OTCPK:CXRX.F) from a group of shareholders. CI
More news
Managers TitleAgeSince
Chief Executive Officer - 22-03-31
Director of Finance/CFO 53 21-12-31
Chief Tech/Sci/R&D Officer - 20-05-31
Members of the board TitleAgeSince
Director/Board Member 55 -
Director/Board Member - -
Chief Executive Officer - 22-03-31
More insiders
ADVANZ PHARMA Corp. Limited is a United Kingdom-based pharmaceutical company. It is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. The Company is focused on investing in product portfolio to optimize healthcare treatment. Its therapy areas include endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders and intensive care medicines. The Company optimizes healthcare treatment through product acquisitions, in-licensing opportunities, product development and alliances worldwide. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products and operates facilities in various locations, including Sydney, Australia; Mumbai, India; Dublin, Ireland; St. Helier, Jersey; Helsingborg, Sweden, and Chicago, United States.
More about the company